TETRAPHASE PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization
Amortization of deferred financing costs and debt discount
Accretion of final interest payment on term loans
Non-cash interest expense related to notes payable
Stock-based compensation expense
Loss from disposal of property and equipment
Loss on extinguishment of debt
Impairment of equipment related to restructuring
Gain on asset disposal
Changes in operating assets and liabilities:
Accounts receivable
Contract asset
Inventory
Prepaid expenses and other assets
Accounts payable
Accrued expenses and accrued final interest payment on term loan
Accrued expenses and other liabilities
Deferred revenue
Operating lease right-of-use assets
Operating lease liabilities

Net cash used in operating activities
Investing activities
Acquisition of intangible assets
Proceeds from sale of property and equipment
Purchases of property and equipment
Proceeds from sale of common stock, net of underwriter discounts and issuance costs
Net cash provided by (used in) investing activities
Financing activities
Repayment of debt, including final payment
Proceeds from sale of common stock and prefunded warrants under registered direct offering, net of issuance costs
Proceeds from issuance of common stock under "at-the-market" equity offering sales agreement, net of issuance costs
Proceeds from exercise of warrant
Proceeds from issuance of debt, net of issuance costs
Proceeds from issuance of stock under stock plans
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Net cash provided by (used in) financing activities
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental cash flow information:
Cash paid for interest
Cash paid for interest on long-term debt

Comments